Psychological and social consequences of community carrier screening programme for cystic fibrosis
- PMID: 1353144
- DOI: 10.1016/0140-6736(92)90477-k
Psychological and social consequences of community carrier screening programme for cystic fibrosis
Abstract
We have assessed the effect of screening for cystic fibrosis (CF) carrier status on anxiety levels, attitudes, knowledge and actions of participants in a pilot programme conducted through primary health care services. Over 3000 individuals were screened and 100 carriers with no previous family history were identified. Varying degrees of anxiety were found to be associated initially with a positive result, but most of this was allayed by genetic counselling, and we find no adverse long-term psychological consequences in carriers. Most discussed carrier status with their partner (89%), parents, other relatives and also with friends; 87% of partners to whom testing was suggested have been screened. Those testing positive indicated that knowledge of carrier status would be considered in future reproductive decisions, and after 6 months carriers retained a reasonable level of knowledge about CF and its inheritance. Carriers and non-carriers uniformly approve of screening and are glad to have been tested. Knowledge of CF in the sample of non-carriers has also increased after testing, suggesting screening may improve understanding of CF among the entire target population. Fears of possible social costs of screening may be ill-founded.
Comment in
-
Screening for cystic fibrosis.Lancet. 1992 Jul 25;340(8813):209-10. Lancet. 1992. PMID: 1353139 No abstract available.
Similar articles
-
Population screening for cystic fibrosis: knowledge and emotional consequences 18 months later.Am J Med Genet A. 2003 Jul 15;120A(2):199-208. doi: 10.1002/ajmg.a.20259. Am J Med Genet A. 2003. PMID: 12833400
-
Psychological impact of population-based carrier testing for cystic fibrosis: 3-year follow-up. UK Cystic Fibrosis Follow-Up Study Group.Lancet. 1996 May 25;347(9013):1443-6. doi: 10.1016/s0140-6736(96)91683-9. Lancet. 1996. PMID: 8676627
-
The impact of population based screening for carriers of cystic fibrosis.J Med Genet. 1994 May;31(5):364-8. doi: 10.1136/jmg.31.5.364. J Med Genet. 1994. PMID: 8064812 Free PMC article.
-
Genetic testing for cystic fibrosis. National Institutes of Health Consensus Development Conference Statement on genetic testing for cystic fibrosis.Arch Intern Med. 1999 Jul 26;159(14):1529-39. Arch Intern Med. 1999. PMID: 10421275 Review.
-
Universal community carrier screening for cystic fibrosis?Nat Genet. 1993 Mar;3(3):195-201. doi: 10.1038/ng0393-195. Nat Genet. 1993. PMID: 8485573 Review.
Cited by
-
Carrier testing of children for two X linked diseases in a family based setting: a retrospective long term psychosocial evaluation.J Med Genet. 1999 Aug;36(8):615-20. J Med Genet. 1999. PMID: 10465112 Free PMC article.
-
PCR-based screening for cystic fibrosis carrier mutations in an ethnically diverse pregnant population.Am J Hum Genet. 1997 Apr;60(4):935-47. Am J Hum Genet. 1997. PMID: 9106541 Free PMC article.
-
Delivery of molecular genetic services within a health care system: time analysis of the clinical workload. The Molecular Genetic Study Group.Am J Hum Genet. 1995 Mar;56(3):760-8. Am J Hum Genet. 1995. PMID: 7887432 Free PMC article.
-
Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease.Cochrane Database Syst Rev. 2018 Mar 14;3(3):CD010849. doi: 10.1002/14651858.CD010849.pub3. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2021 Oct 11;10:CD010849. doi: 10.1002/14651858.CD010849.pub4. PMID: 29537064 Free PMC article. Updated.
-
Cost effectiveness of antenatal screening for cystic fibrosis. Study might be better described as a cost description of screening.BMJ. 1996 Apr 6;312(7035):909-10. doi: 10.1136/bmj.312.7035.909b. BMJ. 1996. PMID: 8611897 Free PMC article. No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical